In vitro cytotoxicity study on platinum (II) complexes with epoxysuccinates as leaving groups

Area of Science:

• Inorganic Chemistry
• Medicinal Chemistry
• Cancer Research

Background:

• Cisplatin is a cornerstone chemotherapy drug, but its efficacy is limited by resistance and toxicity.
• Developing novel platinum-based anticancer agents with improved activity and reduced side effects is crucial.
• Epoxysuccinates and specific carrier ligands can modulate the properties of platinum complexes.

Purpose of the Study:

• To design and synthesize novel cisplatin-type platinum complexes utilizing epoxysuccinates as leaving groups.
• To evaluate the in vitro cytotoxic activities of these novel compounds against human lung and stomach adenocarcinoma cell lines.
• To investigate the structure-activity relationships, particularly the influence of carrier ligands and leaving group stereochemistry on cytotoxicity.

Main Methods:

• Synthesis and characterization of novel platinum complexes using techniques like IR, (1)H NMR, ESI-MS, and elementary analyses.
• In vitro cytotoxicity assays using SPC-A1 (lung adenocarcinoma) and BGC823 (stomach adenocarcinoma) human cell lines.
• Comparative analysis of cytotoxicity based on different carrier ligands and the cis/trans configuration of epoxysuccinate leaving groups.

Main Results:

• The synthesized platinum complexes were successfully prepared and characterized.
• Complexes incorporating the (4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane (DMID) carrier ligand exhibited enhanced cytotoxicity against both cancer cell lines.
• Platinum complexes with trans-epoxysuccinate leaving groups generally displayed higher cytotoxicity compared to those with cis-epoxysuccinates.
• Complex 4a, featuring a trans-epoxysuccinate and DMID ligand, demonstrated the most potent anticancer activity, comparable to cisplatin.

Conclusions:

• Novel platinum complexes with epoxysuccinate leaving groups and DMID carrier ligands show significant potential as anticancer agents.
• The stereochemistry of the epoxysuccinate leaving group (trans isomers) and the nature of the carrier ligand (DMID) are critical factors in determining cytotoxicity.
• Complex 4a represents a promising candidate for further investigation in lung and stomach cancer therapy.